Vilaprisan phase 2B trial: a timely efficacy and safety study of a novel selective progesterone receptor modulator for nonsurgical management of uterine fibroids

Vilaprisan phase 2B trial: a timely efficacy and safety study of a novel selective progesterone receptor modulator for nonsurgical management of uterine fibroids
Uterine fibroids are benign hormone-sensitive tumors of the uterus that often affect women of reproductive age. Although many fibroids are asymptomatic, some women experience distressing symptoms such as heavy menstrual bleeding (HMB), pelvic pressure and/or pain, fertility impairment, and reduced quality of life. Hysterectomy is the definitive cure for uterine fibroids but is associated with complications and cannot be used if fertility preservation is important. Many women would rather avoid surgery and opt for uterus-preserving procedures (UPPs) or medical therapy.
Source: fertstert.org